Company announcement - No. 39 / 2016


Total number of shares and voting rights in Zealand as of 30 September 2016

Copenhagen, 30 September 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand issues announcements to state the total number of shares and voting rights in the company at the end of a calendar month in which there have been changes to its share capital. 

In company announcement no. 34 / 2016 on 6 September 2016 and company announcement no. 35 / 2016 on 23 September 2016, Zealand announced increases in its share capital after exercise of employee warrants. Following from these announcements, the table below lists the total number of shares and voting rights in Zealand as of 30 September 2016.


Number of shares
(nominal value of DKK 1 each)
Share capital
(nominal value in DKK)
Number of votes rights
30 September 2016 24,587,032 24,587,032 24,587,032

The numbers in the table do not include the 1,475,221 new shares recently subscribed for in a completed offering of new Zealand shares as announced by Zealand in Company announcement no. 38 / 2016 earlier today. These new shares will be registered with the Danish Business Authority on 4 October 2016, after which Zealand's share capital will amount to DKK 26,062,253 divided into 26,062,253 shares of nominal value DKK 1 each.


For further information, please contact:

Hanne Leth Hillman, Senior Vice President, Investor Relations and Communications
Tel: +45 50 60 36 89, email:

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn and a pipeline of proprietary product candidates, which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as AdlyxinTM in the United States. Lixisenatide has been developed in a fixed-ratio combination with Lantus® (insulin glargine) which product is under regulatory review in the United States and in Europe. 

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) as single-dose rescue treatment for acute, severe hypoglycemia (Phase II); Glepaglutide* (ZP1848) for treatment of short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and glepaglutide are proposed International Nonproprietary Names (pINN)